A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo, in Adult Subjects With Chronic Idiopathic Constipation

Trial Profile

A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo, in Adult Subjects With Chronic Idiopathic Constipation

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Lubiprostone (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Sponsors Sucampo Pharmaceuticals
  • Most Recent Events

    • 28 Sep 2017 Primary endpoint (Equivalence analysis of observed spontaneous bowel movement (SBM) count at Week 1 for lubiprostone sprinkle vs. lubiprostone capsule) has not been met, according to a Sucampo Pharmaceuticals media release.
    • 22 Aug 2017 Status changed from recruiting to completed.
    • 30 Mar 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top